Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
275.84(c)
273.84(c)
270.28(c)
270.12(c)
269.44(c)
Last
1 765 034
1 214 024
1 293 364
806 526
685 483
Volume
-1.59% -0.73% -1.30% -0.06% -0.25% Change
Sales 2020
13 392 M - -
Net income 2020
4 276 M - -
Net Debt 2020
2 814 M - -
P/E ratio 2020
10,1x
Yield 2020
-
Sales 2021
11 283 M - -
Net income 2021
3 230 M - -
Net Debt 2021
99,5 M - -
P/E ratio 2021
12,1x
Yield 2021
-
Capitalization
41 462 M 41 462 M -
EV / Sales 2020
3,31x
EV / Sales 2021
3,68x
Nbr of Employees
7 400
Free-Float
86,1%
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (15.9%);
- other (4.9%): primarily revenues from partnership agreements.
Notations Surperformance© of Biogen Inc.
Trading Rating : Investor Rating :
All news about BIOGEN INC.
News in other languages on BIOGEN INC.
Analyst Recommendations on BIOGEN INC.
Wall Street rallies on coronavirus vaccine trial results
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIOGEN INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
33
Average target price
294,04 $
Last Close Price
269,44 $
Spread / Highest target
67,0%
Spread / Average Target
9,13%
Spread / Lowest Target
-35,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
